Isoagglutinin‐reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin–associated hemolysis

BACKGROUND: Immunoglobulin therapy including intravenous immunoglobulin (IVIg) has been used as an effective treatment for autoimmune/inflammatory conditions with few side effects. However, high‐dose IVIg (1‐2 g/kg) has been recognized as a cause of hemolytic anemia in non–blood group O patients. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Cen, Selena Y., Branch, Donald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496430/
https://www.ncbi.nlm.nih.gov/pubmed/31837028
http://dx.doi.org/10.1111/trf.15622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496430/
https://www.ncbi.nlm.nih.gov/pubmed/31837028
http://dx.doi.org/10.1111/trf.15622

Ejemplares similares